ArriVent BioPharma, Inc.
AVBPHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ArriVent BioPharma, Inc. focuses on Biotechnology services and products. ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with. Valued at $1.04B, AVBP is a small-cap name in its sector. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Market Cap
$1.04B
Beta
1.35
P/E (TTM)
—
P/E (Fwd)
-5.64
EPS (TTM)
$-3.62
EPS (Fwd)
$-3.72
ROE
-53.3%
ROA
-33.1%
Cash
$373.1M
Total Debt
$351,000
Free CF
-$89.5M
52W Change
7.8%
Annual Financials
Cash vs Debt
Where AVBP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVBP finished 37.23% below its 150-day moving average ($28.58) and 33.80% below its 200-day moving average ($27.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVBP overbought or oversold?
At the October 20, 2026 close, AVBP's RSI(14) was 22.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $373.1M in cash comfortably exceeding the $351K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$89.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -53.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, AVBP has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ArriVent BioPharma, Inc.'s trajectory.